Engineering Immune Organoids to Study Pediatric Cancer

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT05890781
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - 25 Years
Healthy Volunteers
Not accepted

Interventions

  • Skin biopsy — PROCEDURE
    Skin biopsy
  • Fresh tumor sample — PROCEDURE
    Fresh tumor sample
  • Blood sample — BIOLOGICAL
    Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
  • Healthy tissue from the tumor — PROCEDURE
    Healthy tissue from the tumor site whenever possible
  • Spinal cerebrospinal fluid (SCF) — PROCEDURE
    Spinal cerebrospinal fluid (SCF) whenever possible

Study Details

To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)

Key Dates

First listed
Jun 6, 2023
Start date
May 12, 2023
Status verified
Feb 2026
Primary completion
May 31, 2028
Completion
May 31, 2028

Study Design

Enrollment
108 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: Immune organoids from pediatric patient tissues using iPSC
    To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)

Primary Outcome Measure

Proportion of viable and exploitable immune organoids with engrafted tumor cells [ Time Frame: until 5 years after enrolment ]

Central Contacts

Find similar trials

Nationwide
Brain cancer trialsNeuroblastoma trialsOncology trialsNeuro-oncology trialsPediatric oncology trials

Related Studies